NICHOLAS SLUSS: Open Payments
NPI 1093924201 · NORTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,157 in 71 payments from 19 companies in 2025. Trend: 2023 $1,430 · 2024 $2,252 · 2025 $1,157
Food & beverage: $1,157
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $264 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $203 |
| ABBVIE INC. | 16 | $183 |
| GlaxoSmithKline, LLC. | 6 | $92 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $44 |
| Amgen Inc. | 2 | $36 |
| Dexcom, Inc. | 1 | $35 |
| PFIZER INC. | 2 | $34 |
| Abbott Laboratories | 2 | $33 |
Products named: CAPLYTA, TRELEGY ELLIPTA, VRAYLAR, Ozempic, Rybelsus, Wegovy, AIRSUPRA, QULIPTA.
Industry payments across VA — which companies pay providers there.
